Joanna Phillips, MD, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Joanna Phillips, MD, PhD

Assistant Professor, Neurological Surgery and Pathology; Co-Director UCSF Brain Tumor SPORE Biorepository

joanna.phillips@ucsf.edu

Phone: (415) 514-4929
Box 0520 , UCSF
San Francisco, CA 94143-0520

View on UCSF Profiles

Cancer Center Membership

Program Member » Neurologic Oncology

Research Summary

I am an Assistant Professor in the UCSF Departments of Neurological Surgery and Pathology, Director of the UCSF Brain Tumor Research Center Tissue Biorepository and Histology Core, Co-Director of the UCSF Neuropathology BTRC Biomarkers Laboratory, Co-Director of the UCSF Brain Tumor SPORE Biorepository, and Director of the Biospecimen and Biostatistics Core for a UCSF brain tumor-focused Program Project (P01). I received my MD and PhD in Neuroscience from the University of Pennsylvania School of Medicine in 2002, and I have over ten years of experience working in cancer and neuropathology. My research interests focus on studying how factors in the brain tumor microenvironment, including the extracellular matrix and immune cells, influence tumor development and invasion. I am the PI of an NINDS-funded R01 and an NCI-funded U01, and have published over 70 publications related to the development and therapy of brain tumors.

Education

Cornell University, Ithaca, NY, BS, 05/1994, Biology/Biochemistry
University of Pennsylvania, Philadelphia, PA, PhD, 05/2001, Neuroscience
University of Pennsylvania, Philadelphia, PA, MD, 05/2002, Medicine
University of Washington, Seattle, WA, Residency, 2002-2004, Anatomic Pathology
University of California SF, San Francisco, CA, Fellow, 2004-2006, Neuropathology


Professional Experience

  • 2002–2004
    Resident, Department of Anatomic Pathology, University of Washington
  • 2004–2006
    Clinical Fellow, Department of Pathology, University of California San Francisco
  • 2006-2008
    Postdoctoral Fellow, Mentor: Zena Werb, Ph.D., Department of Anatomy, University of California San Francisco
  • 2008–2010
    Clinical Instructor, Department of Pathology, University of California San Francisco
  • 2009-Present
    UCSF Brain Tumor Research Center Tissue Bank, Neuropathologist
  • 2010-Present
    Assistant Professor Neurological Surgery and Pathology, University of California, San Francisco
  • 2010-Present
    Co-Director UCSF Brain Tumor SPORE Biorepository
  • 2012-Present
    UCSF Helen Diller Family Comprehensive Cancer Center, Member
  • 2012-Present
    Society for Glycobiology

Honors & Awards

  • 1993-94
    Cornell University, Hughes Scholars Program
  • 1994
    Cornell University, graduated with honors and distinction in Biology
  • 1999
    American Society for Virology travel award
  • 2001
    Stuart Mudd Award in Microbiology, University of Pennsylvania School of Medicine
  • 2005
    Moore Award for best paper on clinico-pathologic correlation, annual meeting of American Association of Neuropathologists
  • 2006
    Nominated UCSF School of Medicine Essential Teaching Award
  • 2006
    Young Pathologist Fellowship, American Society for Investigative Pathology, Experimental Biology annual meeting
  • 2006-08
    American Brain Tumor Association: Susan Resnick Fisher/American Brain Tumor Association Fellowship
  • 2008
    Rubinstein Award, best paper on neuro-oncology, annual meeting of American Association of Neuropathologists
  • 2010
    Aspen Cancer Conference Fellow
  • 2012
    Second place, Moore Award, Best paper on clinic-pathological correlation, annual meeting of American Association of Neuropathologists
  • 2013
    Nominated UCSF School of Medicine Essential Core Teaching Award

Selected Publications

  1. Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells. Cancer Res. 2015 Dec 15; 75(24):5355-66.
    View on PubMed
  2. DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors. Cancer Cell. 2015 Sep 14; 28(3):307-17.
    View on PubMed
  3. IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism. Cancer Res. 2015 Aug 1; 75(15):2999-3009.
    View on PubMed
  4. CDKN2A Loss Is Associated With Shortened Overall Survival in Lower-Grade (World Health Organization Grades II-III) Astrocytomas. J Neuropathol Exp Neurol. 2015 May; 74(5):442-52.
    View on PubMed
  5. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol. 2015 Aug; 17(8):1051-63.
    View on PubMed
  6. Proportional Upregulation of CD97 Isoforms in Glioblastoma and Glioblastoma-Derived Brain Tumor Initiating Cells. PLoS One. 2015; 10(2):e0111532.
    View on PubMed
  7. Metabolic Reprogramming in Mutant IDH1 Glioma Cells. PLoS One. 2015; 10(2):e0118781.
    View on PubMed
  8. Glycosylation alterations in lung and brain cancer. Adv Cancer Res. 2015; 126:305-44.
    View on PubMed
  9. Measuring sulfatase expression and invasion in glioblastoma. Methods Mol Biol. 2015; 1229:507-16.
    View on PubMed
  10. Practical molecular pathology and histopathology of embryonal tumors. Surg Pathol Clin. 2015 Mar; 8(1):73-88.
    View on PubMed
  11. SULF2, a heparan sulfate endosulfatase, is present in the blood of healthy individuals and increases in cirrhosis. Clin Chim Acta. 2015 Feb 2; 440:72-8.
    View on PubMed
  12. Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase. PLoS One. 2014; 9(9):e108289.
    View on PubMed
  13. Epidermal growth factor-like module containing mucin-like hormone receptor 2 expression in gliomas. J Neurooncol. 2015 Jan; 121(1):53-61.
    View on PubMed
  14. Characterization of metabolites in infiltrating gliomas using ex vivo ¹H high-resolution magic angle spinning spectroscopy. NMR Biomed. 2014 May; 27(5):578-93.
    View on PubMed
  15. Matrix regulators in neural stem cell functions. Biochim Biophys Acta. 2014 Aug; 1840(8):2520-5.
    View on PubMed
  16. Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet. 2013 Dec; 45(12):1428-30.
    View on PubMed
  17. Current management of choroid plexus carcinomas. Neurosurg Rev. 2014 Apr; 37(2):179-92; discussion 192.
    View on PubMed
  18. Na?/K?-ATPase ß2-subunit (AMOG) expression abrogates invasion of glioblastoma-derived brain tumor-initiating cells. Neuro Oncol. 2013 Nov; 15(11):1518-31.
    View on PubMed
  19. The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas. Mod Pathol. 2013 Nov; 26(11):1425-32.
    View on PubMed
  20. Tuberculoma of the central nervous system. J Clin Neurosci. 2013 Oct; 20(10):1333-41.
    View on PubMed

Go to UCSF Profiles, powered by CTSI